Apellis Pharmaceuticals (NASDAQ:APLS) Receives “Buy” Rating from HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $57.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 96.35% from the stock’s previous close.

APLS has been the topic of a number of other reports. Oppenheimer decreased their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird decreased their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Citigroup cut their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Mizuho dropped their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Finally, Piper Sandler decreased their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.65.

Apellis Pharmaceuticals Stock Up 4.8 %

APLS stock opened at $29.03 on Tuesday. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -14.30 and a beta of 0.94. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 12-month low of $24.34 and a 12-month high of $71.90. The company has a 50 day moving average of $31.86 and a two-hundred day moving average of $33.45.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.17) EPS. On average, equities analysts anticipate that Apellis Pharmaceuticals will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, CEO Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the sale, the chief executive officer now directly owns 307,415 shares in the company, valued at approximately $8,822,810.50. This trade represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00. Following the transaction, the chief financial officer now owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. The trade was a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,308 shares of company stock valued at $511,406. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. True Wealth Design LLC purchased a new position in Apellis Pharmaceuticals in the third quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $56,000. KBC Group NV boosted its stake in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).